4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cardiovascular Research

Background:

• Platelet-activating factor (PAF) is a potent lipid mediator involved in inflammation and thrombosis.
• Developing specific antagonists for PAF is crucial for treating PAF-mediated diseases.
• 1,4-dihydropyridines (1,4-DHP) represent a class of compounds with diverse biological activities.

Purpose of the Study:

• To synthesize and evaluate novel 1,4-dihydropyridine derivatives as potential PAF antagonists.
• To assess the specificity of these compounds against PAF-induced platelet aggregation and hypotension.
• To investigate the cardiovascular safety profile of the most promising candidates.

Main Methods:

• Synthesis of a series of 4-alkyl-1,4-dihydropyridines.
• In vitro assays for inhibition of washed rabbit platelet aggregation induced by PAF-acether.
• In vivo studies to evaluate the reversal of PAF-induced hypotension in anesthetized rats.
• Assessment of radiolabeled PAF binding to platelet receptors.
• Evaluation of calcium channel blocker activity and cardiovascular effects in rats.

Main Results:

• Compounds 6I and 6L demonstrated potent and specific antagonism of PAF-induced platelet aggregation.
• Neither 6I nor 6L induced platelet aggregation or inhibited aggregation induced by collagen or ADP.
• Compound 6L showed no in vitro calcium channel blocker activity and no cardiovascular effects in vivo.
• Compound 6L exhibited a Ki value of 568.62 nmol for PAF receptor binding.

Conclusions:

• Compound 6L is a highly potent and specific PAF antagonist based on its 1,4-dihydropyridine structure.
• Compound 6L lacks significant cardiovascular activity associated with calcium channel blockade.
• These findings highlight compound 6L as a promising therapeutic candidate for PAF-related conditions.